Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

The following is a summary of “Impact of critical illness on continuation of anticancer treatment and prognosis of patients with aggressive hematological malignancies,” published in the September 2024 ...

The study did not provide details on the proportion of patients with therapy-related or secondary acute myeloid leukaemia, and on those with a poor or intermediate-risk karyotype. Complete remission ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

Phase II trial of the novel combination, decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...